GlassScriptPhysician profile
Jessica L Lee
NPI 1003461831
$1,723.25
in general payments reported to CMS, 2019-2025
24 companies · $1,056 in 2025
The $1,056 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $123 · 2023: $347 · 2024: $198 · 2025: $1,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,599.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $369.78 | 2022-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $214.21 | 2023-2025 | Jynarque |
| Novartis Pharmaceuticals Corporation | $157.30 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.09 | 2023-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $113.84 | 2024-2025 | Tarpeyo |
| Amgen INC. | $89.98 | 2024-2025 | Tavneos |
| Novo Nordisk INC | $77.61 | 2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $72.36 | 2025 | Jardiance |
| Mallinckrodt Hospital Products INC. | $70.29 | 2025 | Acthar, Terlivaz |
| Madrigal Pharmaceuticals | $63.39 | 2025 | Rezdiffra |
| Sandoz INC. | $53.15 | 2025 | Hyrimoz |
| Exact Sciences Corporation | $45.86 | 2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $36.69 | 2025 | |
| Apellis Pharmaceuticals, INC. | $35.88 | 2025 | Empaveli |
| Merck Sharp & Dohme LLC | $23.72 | 2025 | Prevymis |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recor Medical INC | $23.29 | 2025 | Paradise Ultrasound Renal Denervation System |
| Scpharmaceuticals INC. | $21.13 | 2025 | |
| Ardelyx, INC. | $21.02 | 2024 | Ibsrela |
| Travere Therapeutics, INC. | $20.23 | 2025 | |
| Corcept Therapeutics | $19.99 | 2025 | Korlym |
| Ultragenyx Pharmaceutical INC. | $19.08 | 2024 | Crysvita |
| Alexion Pharmaceuticals, INC. | $17.31 | 2025 | Ultomiris |
| Cycle Pharmaceuticals INC | $17.22 | 2025 | Venxxiva |
| Astrazeneca Pharmaceuticals LP | $16.83 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.